Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Outcomes and toxicities in patients with diffuse-large B cell lymphoma involving the gastrointestinal tract and digestive organs.
Manzar GS, Cha EE, Corrigan KL, Yoder AK, Schrank BR, Nasr LF, Chihara D, Castillo LM, Nair R, Jain P, Neelapu SS, Rodriguez MA, Strati P, Nastoupil LJ, Gunther JR, Dabaja BS, Pinnix CC, Wu SY, Fang PQ. Manzar GS, et al. Among authors: nasr lf. Front Oncol. 2024 Sep 11;14:1447020. doi: 10.3389/fonc.2024.1447020. eCollection 2024. Front Oncol. 2024. PMID: 39324011 Free PMC article.
Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL.
Zhao Y, Short NJ, Kantarjian HM, Chang TC, Ghate PS, Qu C, Macaron W, Jain N, Thakral B, Phillips AH, Khoury J, Garcia-Manero G, Zhang W, Fan Y, Yang H, Garris RS, Nasr LF, Kriwacki RW, Roberts KG, Konopleva M, Jabbour EJ, Mullighan CG. Zhao Y, et al. Among authors: nasr lf. medRxiv [Preprint]. 2023 Dec 9:2023.12.06.23299616. doi: 10.1101/2023.12.06.23299616. medRxiv. 2023. Update in: Blood. 2024 Jul 4;144(1):61-73. doi: 10.1182/blood.2024023930 PMID: 38106221 Free PMC article. Updated. Preprint.
Characterization of Lymphopenia and Correlating the Risk of Cytopenias With Dose and Bone Marrow Volume Irradiated in Aggressive B Cell Lymphoma Patients Bridged With Radiation Therapy for Chimeric Antigen Receptor-T Cell Therapy.
Manzar GS, Wu SY, Dudzinski SO, Cha EE, Yoder AK, Corrigan KL, Nasr LF, Sallard G, Ahmed S, Fayad LE, Chihara D, Nair R, Westin JR, Daher M, Neelapu SS, Nastoupil LJ, Gunther JR, Pinnix CC, Dabaja BS, Strati P, Fang PQ. Manzar GS, et al. Among authors: nasr lf. Int J Radiat Oncol Biol Phys. 2024 Sep 19:S0360-3016(24)03394-7. doi: 10.1016/j.ijrobp.2024.09.023. Online ahead of print. Int J Radiat Oncol Biol Phys. 2024. PMID: 39303997
Ultra-Low-Dose Radiation for Extranodal Marginal Zone Lymphoma of the Lung.
Wu SY, Fang PQ, Fetooh A, Manzar GS, Corrigan KL, Schrank BR, Nasr L, Chihara D, Castillo LEM, Nair R, Steiner RE, Jain P, Neelapu SS, Strati P, Nastoupil LJ, Dabaja BS, Pinnix CC, Gunther JR. Wu SY, et al. Adv Radiat Oncol. 2024 Sep 27;9(12):101648. doi: 10.1016/j.adro.2024.101648. eCollection 2024 Dec. Adv Radiat Oncol. 2024. PMID: 39524525 Free PMC article.
Outcome of Patients With Central Nervous System Multiple Myeloma (CNS-MM) Treated With CNS-Directed Radiation Therapy.
Manzar GS, Dudzinski SO, Yoder AK, Seo A, Nasr LF, Rafei H, Becnel MR, Patel KK, Lee HC, Kaufman GP, Gaballa MM, Ye JC, Saini N, Thomas SK, Amini B, Orlowski RZ, Dabaja BS, Pinnix CC, Gunther JR, Wu SY, Fang PQ. Manzar GS, et al. Among authors: nasr lf. Clin Lymphoma Myeloma Leuk. 2024 Nov 22:S2152-2650(24)02422-4. doi: 10.1016/j.clml.2024.11.010. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2024. PMID: 39709251
A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents.
Short NJ, Muftuoglu M, Ong F, Nasr L, Macaron W, Montalban-Bravo G, Alvarado Y, Basyal M, Daver N, Dinardo CD, Borthakur G, Jain N, Ohanian M, Jabbour E, Issa GC, Qiao W, Huang X, Kanagal-Shamanna R, Patel KP, Bose P, Ravandi F, Delumpa R, Abramova R, Garcia-Manero G, Andreeff M, Cortes J, Kantarjian H. Short NJ, et al. J Hematol Oncol. 2023 Jul 8;16(1):73. doi: 10.1186/s13045-023-01476-8. J Hematol Oncol. 2023. PMID: 37422688 Free PMC article. Clinical Trial.
Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML.
Short NJ, Daver N, Dinardo CD, Kadia T, Nasr LF, Macaron W, Yilmaz M, Borthakur G, Montalban-Bravo G, Garcia-Manero G, Issa GC, Chien KS, Jabbour E, Nasnas C, Huang X, Qiao W, Matthews J, Stojanik CJ, Patel KP, Abramova R, Thankachan J, Konopleva M, Kantarjian H, Ravandi F. Short NJ, et al. Among authors: nasr lf. J Clin Oncol. 2024 May 1;42(13):1499-1508. doi: 10.1200/JCO.23.01911. Epub 2024 Jan 26. J Clin Oncol. 2024. PMID: 38277619 Clinical Trial.
Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL.
Kantarjian H, Short NJ, Haddad FG, Jain N, Huang X, Montalban-Bravo G, Kanagal-Shamanna R, Kadia TM, Daver N, Chien K, Alvarado Y, Garcia-Manero G, Issa GC, Garris R, Nasnas C, Nasr L, Ravandi F, Jabbour E. Kantarjian H, et al. J Clin Oncol. 2024 Dec 20;42(36):4246-4251. doi: 10.1200/JCO.24.00272. Epub 2024 Jul 19. J Clin Oncol. 2024. PMID: 39028925
A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia.
Short NJ, Jabbour E, Jain N, Senapati J, Nasr L, Haddad FG, Li Z, Hsiao YC, Yang JJ, Pemmaraju N, Ohanian M, Wierda WG, Montalban-Bravo G, Borthakur G, Han L, Xiao L, Huang X, Abramova R, Zhao M, Garris R, Konopleva M, Ravandi F, Kantarjian H. Short NJ, et al. Blood Adv. 2024 Feb 27;8(4):909-915. doi: 10.1182/bloodadvances.2023012231. Blood Adv. 2024. PMID: 38207208 Free PMC article. Clinical Trial.
16 results